IMRA News and Press, IMARA Inc. From 08/14/20

Imara (NASDAQ: IMRA ) : Q2 GAAP EPS of -$0.59 misses by $0.04 . More news on: IMARA Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trial Reported Phase 2a interim safety and efficacy data at the European Hematology Association Annual Congress and promising clinical ...

Imara (NASDAQ: IMRA ) has dosed first patient in Ardent Phase 2b trial of IMR-687 for adult patients with sickle cell disease. Topline data from the trial is expected in the next quarter. More news on: IMARA Inc., Healthcare stocks news, Read more ...

BOSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced dosing of the first...

BOSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company wi...